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Background: Because of its important effects, as an epigenetic factor, on gene expression and disease
development, DNA methylation has drawn much attention from researchers. Detecting differentially methylated loci
is an important but challenging step in studying the regulatory roles of DNA methylation in a broad range of
biological processes and diseases. Several statistical approaches have been proposed to detect significant
methylated loci; however, most of them were designed specifically for case-control studies.
Results: Noticing that the age is associated with methylation level and the methylation data are not normally
distributed, in this paper, we propose a nonparametric method to detect differentially methylated loci under
multiple conditions with trend for Illumina Array Methylation data. The nonparametric method, Cuzick test is used
to detect the differences among treatment groups with trend for each age group; then an overall p-value is
calculated based on the method of combining those independent p-values each from one age group.
Conclusions: We compare the new approach with other methods using simulated and real data. Our study shows
that the proposed method outperforms other methods considered in this paper in term of power: it detected more
biological meaningful differentially methylated loci than others.
Keywords: Cuzick test, Nonparametric test, Trend testBackground
DNA methylation is an epigenetic mark that has important
effects on transcriptional regulation, chromosomal stability,
genomic imprinting, and X-inactivation, [1,2]. In addition,
it is associated with many human diseases, including
various types of cancer [3-10].
Due to the recent advances of BeadArray technology,
high-throughput genome-wide methylation data can be
routinely generated by Infinium Methylation Assays. This
provides good opportunities for researchers to simultan-
eously study hundreds of thousands of DNA methylation
loci. However, it also requires sophisticated and advanced
statistical methods to analyze this kind of data.
The raw data generated from BeadArray are fluores-
cent intensities for each locus; they need appropriate* Correspondence: zc3@indiana.edu
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unless otherwise stated.preprocesses, such as background correction and
normalization. Then a summarized β-value is gener-
ated from about 30 replicates in the same array as follows:
β ¼ max M;0ð Þmax U;0ð Þþ100 , where M is the average signal from a
methylated allele while U is that from an unmethylated
allele. Obviously, the β-values are continuous numbers
between 0 and 1, with 0 stands for totally unmethy-
lated and 1 for completely methylated.
Due to the non-normality of the β-value [11-13], those
commonly used statistical methods, such as t-test for case
control designs, ANOVA for multiple conditions, or linear
regression with age as a predictor, usually have low power
to detect differentially methylated loci [13,14]. Some statis-
tical approaches with or without adjusting the age-effect,
which has been found highly associated with DNA methy-
lation [15,16], have been proposed to detect differentially
methylated loci for case-control designs [11-13]. However,
very little work has been done for the situation where there
are three or more groups (e.g., conditions, or treatments).td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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age-effect adjustment for DNA methylation data with
three treatments, and found that the method based on
the nonparametric Kruskal-Wallis (KW) test is usually
more powerful than other methods, such as ANOVA
and regression method [14]. However, if there is a trend
associated with treatments or conditions, KW based test
is no longer the optimal method since it ignores this in-
formation. In this case, a more powerful statistical ap-
proach is desirable.
In this paper, we propose a new statistical approach to
detecting differentially methylated loci for methylation
data with multiple conditions with trend. In this method,
we also adjust the age-effect in a similar way that we
used before. More specifically, we first group subjects
into several categories based on their age; we then
apply a nonparametric trend test and get a one-sided
p-value for each age category. An overall p-value is then
obtained through combining those individual p-values.
The performance of the new approach is assessed
through comparing it with other methods using simu-
lated data and a real methylation data set with three
treatments. The R code for the new method is provided
(please see the Additional file 1: R code).
Methods
Existing methods
In a recent paper, we have proposed several methods
based on combining independent p-values to adjust the
effect of age for genome-wide methylation data with
multiple conditions [14]. Since those commonly used
methods, such as regression models with age as continuous
or categorical covariate, have poor performances [12], we
compare the proposed approach with the following ones,
which have the best performances among current methods
based on our previous study [14].
Combined ANOVA test
We assume there are K conditions (treatments) and G
age groups. For each age group g (g = 1,2,…,G), we apply
an ANOVA test and obtain a p-value pAg NOVA: We
know that under the null hypothesis that this locus is
not differentially methylated among K conditions in





has a chi-square dis-
tribution with 2G degrees of freedom (df ) since these G
p-values are independent. Therefore, the overall p-value
can be obtained through combining p-values by Fisher
test [17]:






Similarly, we replace ANOVA by the nonparametric
Kruskal-Wallis test for each age group and obtain an
overall p-value with pANOVAg being replaced by the p-value
pKWg from KW test:






Methods for combining p-values
Besides the Fisher method mentioned above, we can
also use Z-test to combine p-values from independ-
ent tests [18-20]. We calculated the weighted Z stat-










n2g , where ng is the total sample
size in age group g and Φ is the cumulative distribution
function (CDF) of the standard normal distribution. It can
be shown that under the null hypothesis this statistic has
the standard normal distribution. The overall p-value is
then calculated as 1- Φ(Z) by the one-sided z-test.
The proposed method
If there is a monotonic trend of the outcome (i.e., β-value
here) over the treatments, we can use the more powerful
one-sided Cuzick test [21] to obtain a p-value for each age
group g (g = 1,2,…,G). The Cuzick test statistic for age
group g is calculated as:
Cg ¼
XNg














where Ng is the total number of subjects in age group g,
rgi is the rank of the i
th of the Ng subjects, sgk is the score
of the kth (k = 1, 2,…, K) treatment, K is the number of
treatments, pgk ¼ ngkNg , and ngk is the number of subjects
in the kth treatment within the gth age group. For the
kth treatment, we assign a score sgk to each of the ngk
subjects. In this paper, we set sgk = k (k = 1, 2,…, K),
that is, we use scores 1,2,…,K.
It can be shown that under the null hypothesis, the
statistic Cg (g = 1,2,…,G ) in (3) has an asymptotic standard
normal distribution [21]. If there is an increasing trend over
the K treatments, we should use the one-sided p-value,
pr,g = Prob(Z > cg) = 1 −Φ(cg). On the other hand if there
is a decreasing trend over the K treatments, we should use
the other one-sided p-value, pl,g = Prob(Z < cg) =Φ(cg). The
Chen et al. BMC Bioinformatics 2014, 15:142 Page 3 of 7





has an asymptotic chi-
square distribution with 2G df under the null hypothesis
according to Fisher [17]. Similarly, under the null hypoth-






asymptotic chi-square distribution with 2G df.
If we know the direction of the trend (increasing or
decreasing), we should use either W1 or W2 to calcu-
late the overall p-value. However, if the trend direction
is unknown, which is usually the case in practice, we
will use the maximum of the two statistics:
W ¼ max W 1;W 2ð Þ ð4Þ
Since W1 and W2 are correlated, the null distribution of
W is not easy to obtain. However, we have the following
nice result [22-27].
Theorem 1 Under the null hypothesis, the survival func-
tion ofW in (4) is asymptotically bounded by
2γ−γ2≤Pr W > wð Þ≤2γ; ð5Þ
where γ ¼ 1−χ22G wð Þ; and χ22G :ð Þ is the cumulative distri-
bution function of the chi-square distribution with 2G df.
The above theorem can be proved using the concept
of associated variables due to Esary, Proschan and Walkup
[28] and Theorem 2 of Owen [29]. From theorem 1, the
overall p-value can be estimated by the upper bound 2γ.
It is easily seen that when the true p-value of W is small,
the difference between the true and the estimated p-values
is negligible.










where the weight wg ¼ ngN , and ng (g = 1,2,…,G) is the
number of total subjects of the K treatments within the
gth age group. The validity of (6) is easily seen: under
the null hypothesis cg and therefore wgcg has an asymp-
totic standard normal distribution; a two-sided p-value
then can be obtained through (6).
Simulation settings
To assess the performance of the proposed method, we
use simulated data to compare the proposed test with
current methods in terms of controlling type I error rate
and power. We assume there are three different treat-
ments (i..e, K = 3) and six age groups (i.e., G = 6). For
each treatment we assume the β-value has the same
following distributions over the six age groups: (i) uni-
form U(a,b) where 0 ≤ a < b ≤ 1, (ii) truncated normalTN (μ, σ2, 0, 1) (or simply TN (μ, σ2), and (iii) Beta distribu-
tion Beta (c,d) with various parameters. We consider rela-
tively small sample sizes in our simulation study. To reflect
practical situations, we either choose 20 samples for each of
the three treatments (sample size = (20, 20, 20)), or set the
sample sizes as 15, 20, and 25 (sample size = (15, 20, 25)),
respectively, for the three treatments. Since the proposed
test is designed to detect differentially methylated loci when
there is a monotonic trend over the treatments, we simu-
late β-values with increasing or decreasing mean values
over the three treatments for the alternative hypotheses.
For example, in simulation, we first generate 20 β-values
(sample size = (20, 20, 20)) from three uniform distributions
(denoted by a = (0,0,0.25), b = (1,1,1)), U(0,1), U(0,1), and
U(0.25, 1) for each of the three treatment groups. The sig-
nificance level is set to be 0.05 in simulation study. The
type I error rate and power are estimated by the propor-
tions of rejection with 104 replicates.
A real data set
The real methylation data set of the United Kingdom
Ovarian Cancer Population Study (UKOPS) [16], which is
one of the largest available Illumina methylation data sets,
will be used for real data application. This data set originally
includes 274 healthy controls, 131 pre-treatment cases,
and 135 post treatment cases. If the DNA methylation of
a locus is positively associated with the disease, we
would expect that the methylation rates are increasing
from control to post-treatment then to pre-treatment.
On the other hand, if the association is negative, there
would be a decreasing trend over the three conditions:
control, post-treatment, and pre-treatment. In either
of the two situations, we can use the proposed test.
The above mentioned methylation data were generated
by the Illumina Infinium Human Methylation27 BeadChip
and can be downloaded from the NCBI Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo) with the acces-
sion number GSE19711. For this data set, there are 27578
loci. After a data quality control process, we removed 60
subjects with BS values less than 4000 or the coverage rates
less than 95%. All of the subjects are separated into 6 age
groups (50-55, 55-60, 60-65, 65-70, 70-75, and 75 and over).
Table 1 lists the resulting numbers of subjects in each
age by treatment group. For each locus, we apply the
proposed test and other methods.
Results
Simulation results
For the new method and the combined ANOVA and
KW tests, we only report the results using Fisher
method to combine independent p-values, as the re-
sults using Z-test are very similar. Table 2 reports the
empirical type I error rates for the proposed method,
the combined ANOVA test and the combined KW test,
Table 1 Number of samples in age by treatment group
used in the paper after data quality control step
Age group Control Pre-treat Post-treat Total
50_55 14 15 16 45
55_60 61 17 25 103
60_65 64 17 22 103
65_70 35 17 21 73
70_75 63 24 22 109
75_over 20 18 9 47
Total 257 108 115 480
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the sample size is relatively small and the underlying dis-
tribution is not normal, all the methods, including the
ANOVA based test, control type I error rate quite well.
Table 3 lists the empirical power values for the three
methods under various situations. As expected, the pro-
posed test always has higher power values than those of
the combined ANOVA and KW tests. This demonstrates
that the proposed test which uses the trend information
can improve the detecting power. It should point out that
in the simulation study, we assign scores 1, 2, and 3 to theTable 2 Empirical size for each method at significance level 0
Simulation setting (3 treatments)
Distribution Sample size Parameters
Uniform U(a,b) (20,20,20) a = (0,0,0), b = (1,1,1)
a = (0,0,0), b = (0.5,0.5,
a = (0.5,0.5,0.5), b = (1,
(15,20,25) a = (0,0,0), b = (1,1,1)
a = (0,0,0), b = (0.5,0.5,
a = (0.5,0.5,0.5), b = (1,
Truncated Normal TN (μ ,σ2) (20,20,20) μ = (0.5,0.5,0.5), σ = (
μ = (0.5,0.5,0.5), σ = (
μ = (0.2,0.2,0.2), σ = (
μ = (0.8, 0.8, 0.8), σ =
(15,20,25) μ = (0.5,0.5,0.5), σ = (
μ = (0.5,0.5,0.5), σ = (
μ = (0.2,0.2,0.2), σ = (
μ = (0.8, 0.8, 0.8), σ =
Beta (c,d) (20,20,20) c = (1,1,1), d = (1,1,1)
c = (1,1,1), d = (5,5,5)
c = (5,5,5), d = (1,1,1)
c = (5,5,5), d = (5,5,5)
(15,20,25) c = (1,1,1), d = (1,1,1)
c = (1,1,1), d = (5,5,5)
c = (5,5,5), d = (1,1,1)
c = (5,5,5), d = (5,5,5)three treatments. However, the effect sizes between treat-
ments 1 and 2 and that between treatments 2 and 3 are
not set to be 1 to 2, respectively, which makes the scores
(1,2,3) optimal; therefore, the proposed test have the best
power. In words, we don’t use the optimal scores for the
Cuzick test to reflect the real situations when the optimal
scores are unknown. This can be seen from the powers of
the new test with different scores (e.g., (1,1,2), and (1,3,2))
in the last two columns of Table 3. For many situations
considered in Table 3, the scores (1,1,2) are closer to the
optimal scores, which are determined by the effect sizes of
treatments 2 vs. 1, and treatments 3 vs. 1, than the default
ones, (1,2,3); therefore, it is not surprising that the new
test with scores (1,1,2) has larger power values than those
from the one with scores (1,2,3). However, for most of the
situations, the scores (1,3,2) do not use the trend correctly
and hence has lower power compared with the other two.
Results from the real data application
The proposed test and the combined ANOVA and KW
tests are applied to the real data mentioned above. Due to
the multiple comparison issue and the correlation among
loci, it is desirable but difficult to obtain a meaningful cut-
off p-value to determine differentially methylated loci. We.05 with 104 replicates from the simulation study
Combined ANOVA Combined K-W New
0.051 0.045 0.047
0.5) 0.051 0.045 0.045
1,1) 0.055 0.046 0.047
0.052 0.043 0.046
0.5) 0.052 0.044 0.050
1,1) 0.049 0.040 0.043
1,1,1)/5 0.050 0.043 0.048
1,2,3)/5 0.058 0.050 0.045
1,1,1)/5 0.049 0.050 0.043
(1,1,1)/5 0.046 0.043 0.048
1,1,1)/5 0.050 0.046 0.045
1,1.2,1.3)/5 0.053 0.041 0.033
1,1,1)/5 0.050 0.046 0.051









Table 3 Empirical power for each method at significance level 0.05 with 104 replicates from the simulation study





Distribution Sample size Parameters
Uniform U(a,b) (20,20,20) a = (0,0,0.25), b = (1,1,1) 0.699 0.607 0.877 0.962 0.069
a = (0,0.1,0.1), b = (0.5,0.5,0.5) 0.450 0.339 0.724 0.830 0.726
a = (0.6,0.6,0.5), b = (1,1,1) 0.460 0.338 0.695 0.821 0.027
(15,20,25) a = (0,0,0.25), b = (1,1,1) 0.809 0.692 0.926 0.980 0.957
a = (0,0.1,0.1), b = (0.5,0.5,0.5) 0.433 0.319 0.618 0.758 0.218
a = (0.6,0.6,0.5), b = (1,1,1) 0.482 0.380 0.754 0.854 0.860
Truncated Normal TN (μ, σ2) (20,20,20) μ = (0.1,0.1,0.2), σ = (1,1,1)/5 0.451 0.394 0.743 0.862 0.052
μ = (0.1,0.1,0.2), σ = (1,1.2,1.3)/5 0.773 0.642 0.962 0.954 0.200
μ = (0.5,0.5,0.4), σ = (1,1,1)/5 0.691 0.656 0.918 0.976 0.054
μ = (0.5,0.5,0.4), σ = (1,1.2,1.3)/5 0.402 0.374 0.696 0.820 0.032
(15,20,25) μ = (0.1,0.1,0.2), σ = (1,1,1)/5 0.464 0.428 0.786 0.886 0.948
μ = (0.1,0.1,0.2), σ = (1,1.2,1.3)/5 0.735 0.643 0.959 0.952 0.713
μ = (0.5,0.5,0.4), σ = (1,1,1)/5 0.775 0.738 0.949 0.981 0.827
μ = (0.5,0.5,0.4), σ = (1,1.2,1.3)/5 0.382 0.364 0.756 0.838 0.852
Beta (c,d) (20,20,20) c = (1,1,1), d = (30,40,50) 0.596 0.442 0.889 0.723 0.432
c = (1,1.2,1.5), d = (40,40,40) 0.490 0.609 0.962 0.920 0.329
c = (30,40,50), d = (1,1,1) 0.578 0.450 0.899 0.745 0.420
c = (40,40,40), d = (1,1.2,1.5) 0.488 0.620 0.972 0.924 0.369
(15,20,25) c = (1,1,1), d = (30,40,50) 0.608 0.405 0.861 0.727 0.998
c = (1,1.2,1.5), d = (40,40,40) 0.426 0.602 0.952 0.912 0.559
c = (30,40,50), d = (1,1,1) 0.618 0.409 0.888 0.752 0.458
c = (40,40,40), d = (1,1.2,1.5) 0.450 0.606 0.958 0.919 0.995
Note: 1the prosed test with scores (1,2,3), 2the prosed test with scores (1,1,2), 3the prosed test with scores (1,3,2).
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than a given cutoff value from each method. We choose
different cutoff values: 10−3, 10−4, 10−5, 10−6, 10−7, and
10−8. The results are reported in Table 4. For each of
the given cutoff p-values, the proposed test always de-
tects more loci than the other methods. In addition,
most of the loci detected by the combined ANOVA and
KW tests were also detected by the proposed test. For
example, when the cutoff p-value is 10−5, the combined
ANOVA test , the combined KW test, and the proposedTable 4 Number of significant differentially methylated loci d
Method 1e-3 1e-4 1e
F Z F Z F
T1 (Combined ANOVA) 981 1079 655 690 47
T2 (Combined KW) 1359 1340 823 859 55
T3 (New) 2915 3117 1855 1951 12
T1 and T2 926 980 615 656 44
T1 and T3 931 1018 639 670 47
T2 and T3 1294 1279 806 832 54
T1, T2, and T3 895 954 605 642 43test detected 479, 551, and 1283 loci, respectively, when
Fisher method was used to combine p-values. Out of
the 479 loci detected by the combined ANOVA test, 471
were also detected by the new test; out of the 551 loci
detected by the combined KW test, only 7 were not de-
tected by the proposed test.
This indicates that the proposed test is more power-
ful than other methods that are compared in this
study. It is noticeable that the methods of combining
independent p-values (i.e., Fisher test and Z-test) haveetected by each method for each given cutoff p-value
-5 1e-6 1e-7 1e-8
Z F Z F Z F Z
9 499 350 375 257 275 189 208
1 590 381 401 261 277 172 185
83 1310 905 929 674 686 513 521
2 474 306 338 221 235 152 167
1 491 346 367 252 269 187 206
4 577 377 396 259 276 170 184
7 468 303 336 220 234 151 166
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gives a few more significant loci.
Discussion
We proposed a new statistical approach based on combing
p-values and the Cuzick test, which is a nonparametric
one-sided test. Through simulation study and real data
application, we show that if there exists a monotonic
(not necessarily linear) trend over the treatments, the
proposed test is more powerful than other methods.
Figure 1 plots the mean β-value of each of the three
treatments over the six age groups for loci with p-values less
than 10−3 from the proposed test. From Figure 1, we can see
there is a decreasing trend among the three treatments
(i.e., for the β-value, pre-treatment < post-treatment < control)
for all of the six age groups; while from for those loci with
large p-values, such trend does not exist for any of the six
age groups (see Additional file 2: Figure S1).
Although many methods can detect those loci which
are strongly differentially methylated among different
treatments, it is important to detect loci having small
effects as they are biological meaningful and provide
useful information for set-based analyses, such as gene,
gene-set, and pathway analyses which use those detected
differentially methylated loci as input [30].
To use the Cuzick test, we need to assign a score for each
of the treatment. Here we assign 1, 2, and 3 to the control,
















































































Figure 1 The mean β-value of loci with p-value less than 10−3 from the
For each age group, there is a trend among the three treatments: pre-treatm
smaller β-value than the control group.if we have the information of the effects for each treatment,
we can use this information to assign scores. For example,
for the K-1 treatments 2, 3, …, K, if the effect sizes are
m2, …, mK compared to treatment 1, we can assign scores
0, m2, …, mK to those treatments for the proposed test.
However, if we only know that there is a monotonic trend,
we can choose 1, 2, …, K (equivalent to 0, 1, …, K-1) as the
scores. Although, the performance of the proposed test
can be improved by assigning optimal scores, which are
determined by the true effects, to the treatments; in
general, it is impractical to obtain the optimal scores. In
addition, the optimal scores for each locus may not be
the same across age groups (see Figure 1).
Like other large scale data, such as microarray data
and genome-wide association study data, the multiple
comparison is an important but challenging issue. Al-
though some procedures have been proposed to con-
trol either family-wise error rate or false discovery rate, it
remains an open topic in this area. One possible direction
is to use the so-called “effective number” estimated from
correlations among the loci [31].
Conclusions
We propose a new statistical approach to detecting
methylated loci for high-throughput methylation data
with multiple groups. This approach is based on the
nonparametric Cuzick test, which is robust and powerful












































proposed test over the three treatment groups by the age group.
ent has smaller β-value than the post-treatment group, which in turn has
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existing methods.
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Additional file 1: R code.
Additional file 2: Figure S1. The mean β-value of loci with p-value
greater than 10-3 from the proposed test over the three treatment groups
by the age group. For each age group, there is no obvious trend over
the three treatments for the β-value.
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